Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENEX vs BUPRENORPHINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Treatment of opioid dependence,Management of moderate to severe pain (off-label)
Treatment of opioid dependence (buprenorphine/naloxone combination),Management of moderate to severe pain (buprenorphine transdermal or buccal formulations)
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
Primarily N-dealkylation via CYP3A4; also conjugation by UGT enzymes (UGT1A1, UGT2B7).
Primarily metabolized by CYP3A4 to norbuprenorphine; also glucuronidated by UGT1A1, UGT2B7.
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
96% bound to alpha- and beta-globulins, and albumin.
96% bound primarily to alpha- and beta-globulins, with negligible binding to albumin.
Volume of distribution is 430-600 L (approximately 2.8 L/kg), indicating extensive tissue distribution.
2.5 L/kg (range 1.5-5 L/kg); high Vd indicates extensive tissue distribution (e.g., brain, adipose).
Sublingual: 30-50% (due to first-pass metabolism); buccal: 50-60%; oral: 15-30% (not clinically used); intravenous: 100%.
Sublingual: 30-50% (range 15-55%); buccal: 30-50%; oral: <10% due to extensive first-pass metabolism; intramuscular: 90-100%; intravenous: 100%.
No specific dose adjustment required for GFR >30 m L/min; for GFR 15-30 m L/min, consider cautious dosing and extended intervals; for GFR <15 m L/min, use with caution and consider dose reduction.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution and consider reducing dose or extending interval. Not dialyzable.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use or reduce dose by 75%.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce starting dose by 50% (e.g., sublingual 4 mg). Child-Pugh C: Avoid use or reduce dose by 75% (e.g., sublingual 2 mg).
Not recommended for children under 2 years; for age 2-12 years: 2-6 mcg/kg intramuscularly or intravenously every 4-6 hours; maximum single dose 0.3 mg.
Not approved for <16 years. For induction in adolescents: Sublingual 2-4 mg initially, titrated based on response. Maximum 24 mg/day.
Start with 0.15 mg intramuscularly or intravenously every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Reduce initial dose by 25-50% due to increased sensitivity. Titrate slowly. Monitor for respiratory depression and CNS effects.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of death with intravenous administration; risk of serious adverse events when used with benzodiazepines or other CNS depressants.
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; WARNING: RISK OF NEONATAL OPIOID WITHDRAWAL SYNDROME
Respiratory depression; CNS depression; risk of dependence and abuse; adrenal insufficiency; QT prolongation; severe injection site reactions; risk of precipitating withdrawal in opioid-dependent patients; neonatal withdrawal syndrome; impairment of ability to drive or operate machinery.
Respiratory depression (especially with benzodiazepines or other CNS depressants), neonatal opioid withdrawal syndrome during prolonged use in pregnancy, risk of hepatitis or hepatic injury, adrenal insufficiency, hypotension, QT prolongation, opioid-induced hyperalgesia, risk of withdrawal with partial agonist, misuse potential.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe asthma; GI obstruction; elevated CSF pressure; use of MAOIs within 14 days.
Hypersensitivity to buprenorphine, severe respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (including paralytic ileus), concomitant use with full mu-opioid agonists (risk of precipitated withdrawal).
No specific food interactions are reported. Grapefruit juice has not been shown to significantly alter buprenorphine metabolism. Advise patients to maintain a balanced diet to manage opioid-induced constipation.
No significant food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; concurrent use is not recommended. Avoid excessive alcohol consumption.
Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) and neonatal respiratory depression. Risk of preterm labor and low birth weight. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) requiring monitoring. Use only if benefit outweighs risk.
Buprenorphine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.9. Limited data suggest no adverse effects in breastfed infants at maternal doses up to 24 mg/day. However, monitor infant for sedation and respiratory depression. Benefits of breastfeeding outweigh risks in opioid-dependent mothers on maintenance therapy.
Buprenorphine is excreted in breast milk with a relative infant dose of 1-2% of maternal weight-adjusted dose. M/P ratio approximately 1.0 based on limited data. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for sedation, feeding difficulties, and withdrawal if breastfeeding is abruptly stopped.
No specific dose adjustments are recommended for buprenorphine during pregnancy. However, due to increased plasma volume and hepatic clearance, some patients may require dose increases in the second and third trimesters to avoid withdrawal symptoms. Close monitoring of therapeutic response and withdrawal signs is advised.
No routine dose adjustment required in pregnancy due to minimal pharmacokinetic changes. However, increased clearance in third trimester may necessitate dose increase (typically 2-4 mg/day) to maintain therapeutic effect. Taper to avoid withdrawal prior to delivery is not recommended due to risk of preterm labor and fetal distress.
Buprenorphine (Buprenex) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu-receptors, which can precipitate withdrawal if given to opioid-dependent patients. Monitor for respiratory depression, especially in combination with CNS depressants. Use with caution in hepatic impairment; adjust dose in moderate to severe impairment.
Buprenorphine is a partial mu-opioid agonist; its ceiling effect reduces respiratory depression risk but may precipitate withdrawal in opioid-dependent patients if administered too soon after full agonists. Sublingual tablets require adequate dissolution under the tongue for 5-10 minutes; advise patient not to swallow or talk during dissolution. Naloxone is combined to deter intravenous misuse; sublingual bioavailability of naloxone is low, but intravenous injection can precipitate withdrawal. Avoid use in patients with severe hepatic impairment due to extensive first-pass metabolism. Monitor for QT prolongation, especially at high doses or with concomitant QT-prolonging drugs.
Do not stop taking this medication abruptly as it may cause withdrawal symptoms; follow your doctor's instructions for tapering.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness or respiratory depression.,This medication can cause constipation; increase fluid and fiber intake, and consider stool softeners.,Store securely away from children and pets, as accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or sedatives (benzodiazepines, other opioids) while taking this medication, as it may cause severe drowsiness, respiratory depression, or coma.,Do not drive or operate machinery until you know how buprenorphine affects you; dizziness or drowsiness may occur.,If you miss a dose, take it as soon as remembered; if close to next dose, skip the missed dose and resume normal schedule. Do not double doses.,Store at room temperature away from moisture and heat; keep out of reach of children.,Do not stop abruptly; abrupt discontinuation may cause withdrawal symptoms. Your doctor will taper your dose gradually.,If you experience signs of allergic reaction (rash, hives, swelling, difficulty breathing) or signs of overdose (slow/shallow breathing, severe drowsiness, pinpoint pupils), seek emergency medical attention.,Inform all healthcare providers that you are taking buprenorphine; carry a medication card or alert bracelet.
No interactions on record
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENEX vs BUPRENORPHINE HYDROCHLORIDE, answered by our medical review team.
BUPRENEX is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.. BUPRENORPHINE HYDROCHLORIDE is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENEX and BUPRENORPHINE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENEX is: 0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.. The standard adult dose of BUPRENORPHINE HYDROCHLORIDE is: Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENEX and BUPRENORPHINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENEX is classified as Category C. Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high dos. BUPRENORPHINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.